Americafirst Capital Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, Holdings Channel reports. The fund acquired 8,125 shares of the biopharmaceutical company’s stock, valued at approximately $658,000.

A number of other institutional investors and hedge funds also recently modified their holdings of GILD. BlackRock Inc. increased its stake in Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. increased its stake in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Bank of New York Mellon Corp increased its stake in Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the period. FMR LLC increased its stake in Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Finally, Northern Trust Corp increased its stake in Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. Hedge funds and other institutional investors own 75.84% of the company’s stock.

In other news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the completion of the sale, the executive vice president now owns 70,988 shares in the company, valued at $5,298,544.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.98, for a total value of $5,498,508.34. Following the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,196,023.02. The disclosure for this sale can be found here. Insiders have sold 358,333 shares of company stock valued at $28,066,908 in the last 90 days. Company insiders own 1.30% of the company’s stock.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $79.32 on Monday. The firm has a market capitalization of $103,590.00, a P/E ratio of 22.79, a PEG ratio of -1.75 and a beta of 1.22. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The company has a quick ratio of 3.56, a current ratio of 3.55 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. During the same quarter in the prior year, the business earned $2.70 earnings per share. The company’s quarterly revenue was down 18.7% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences, Inc. will post 6.41 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.87%. The ex-dividend date of this dividend is Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is 59.77%.

A number of brokerages have issued reports on GILD. Mizuho set a $83.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Monday, February 5th. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.25 target price on the stock in a research note on Monday. Bank of America upped their target price on shares of Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. Leerink Swann cut their target price on shares of Gilead Sciences from $86.00 to $83.00 and set a “market perform” rating on the stock in a research note on Wednesday, February 7th. Finally, Morgan Stanley cut their target price on shares of Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 7th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $86.56.

TRADEMARK VIOLATION NOTICE: This article was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://theolympiareport.com/2018/02/12/americafirst-capital-management-llc-takes-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.